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of the antigenic structure of  the parasite, with large numbers of 
different epitopes that are, in part, stage-specific and, furthermore, 
may vary between strains. Adjuvants also influence the type of 
iinniune response. The  growing knowledge of pathogenesis, and 
host-dependent genetic and ininiunologic factors involved in the 
clinical outcome of I-) -falciparrm malaria, and the insight into the 
paracite's evasion iiiechanisiiis, help us to understand the interactions 
of this infectiou, agent with the host's immune system. We now 
believe that malaria vaccines will eventually be available. We do not, 
however, believe that vaccines alone will lead to the eradication of 
this disease. 
The future of global strategies for vaccination: 
WHO perspectives 
P-H. Lainbert. WHO, Vaccine Research G Devel. Uirit, Gencua, 
Switrt~rlarid 
Future vaccination strategies will certainly be related to the potential 
impact of vaccination on  morbidity and mortality directly or 
indirectly associated with specific infectious diseases. About 1.8 
rnillion children die of infection in the neonatal period (0-4 weeks 
of age), particularly in Asia and Africa. The main causes of death are 
bacterial infections caused by Staphylococctrs aurerrs, group A strepto- 
cocci, Streptococcus pnerimoniae, Gram-negative coliforriis and 
Saltnoriella as well as neonatal tetanus. During the post-neonatal 
period (1-12 months), severe infant infections are responsible for over 
2 million deaths. In the developing world, the major causes are acute 
respiratory infections due to pneumococci, Haenmphihrs iqfluenzae or 
pertussis as well as diarrhea caused by rotaviruc, shigella, Salmonella 
or E. coli. This contrasts with the greater importance of respiratory 
viruses (RSV, parainfluenza and influenza), urinary infections, and 
rotavirus diarrhea in industrialized countries. Although a number of 
new vaccines are now becoming available to meet this challenge, 
Vaccination strategies to prevent early-life infectious diseases should 
he selected and adapted accordingly. They will include maternal 
immunization for early neonatal infections, as well as vaccination in 
early infancy (0-3 months) for early-occurring diseases. Problem to 
be solved are inainly related (1) to safety issues (maternal or neonatal 
immunization), (2) to inniiunologic immaturity and T-cell polariz- 
ation (0-3 months imiiiunization), (3) to the duration of induced 
protection and iiieniory, and (4) to inhibition of infant responses by 
maternal antibodies. 
Recent developments in cardiovascular 
infections 
Do w e  still need prophylaxis against infective 
endocarditis? 
E. Gutschik. Departittent qf Clinical Minobiolosy, Eispe&jcR Hospital, 
Urriversiry qf C o p c i i h a p ~ ,  Coprnhapi, Deninark 
The answer is yes, even according to a recent population-based, case- 
control study from Philadelphia, USA (Ann Intern Med 1998;129: 
761-9) challenging the current recomniendations for prophylaxis for 
infective endocarditis (1E). The findings indicate that dental treat- 
ment is not a risk factor. However, differences in dental health, dental 
status and dental care between case patients and controls were not 
considered. This study will not change our attitude towards the 
necessity for antimicrobial prophylaxis. but underlines the need for 
data regarding the correlation between the magnitude of bactereiiiia 
(CFU/inL blood) in connectio~i with dental procedures and the 
incidence of IE. It is likely that prophylaxis should be downgraded 
to 'not recommended' for some dental procedures. Since oral micro- 
organisms are still responsible for most ca5es of IE, it is obvious that 
prevention should be upgraded, with maintenance of better dental 
care in patients at risk for 1E. Prophylaxis 111 children, espccially with 
major congenital heart conditions, requires further investigation and 
discussions. Prevention of  nosoconiial endocarditis represent\ a 
formidable clinical challenge, with the introduction of new card~ic  
devices like implantable cardiovascular defibrillators and left ventri- 
cular assist devices, raising questions of hardware removal in casec of 
infection or chronic suppressive antimicrobial therapy. The  incidence 
and mortality of prosthetic valve endocarditis are still unacceptably 
high. Here also we should focus on prevention (surgical tcchniquec, 
surgical materials, treatment of perioperative bacteremias, dental 
health) rather than efforts to amplify antimicrobial prophylaxis. 
New antibiotic treatment modalities 
J.M. Entenza, J. Vouillanioz, M.P. Glauser, I! Moi-eillon. fr~firrrtirrs 
Diseases, CHUY L a u s a r m ,  Suitrrrlarrd 
Treatment of Staplrylocorcirs a i m u s  and streptococcal endocarditis 
require5 prolonged administration of pareliteral p-lactani\ or vanco- 
niycin. Newer quinoloiies are active against Gram-positive bacteria, 
are well absorbed after oral administration. and have .i pi-olonged 
seruiii f l / 2 ,  allowing once-daily dosage. Levofloxacin, trovafloxacin 
and moxifloxacin were tested in rats with S. awc'irs or streptococcal 
experimental endocarditis (EE). They were compared to cipro- 
floxacin (Cipro) and vancomyciii (Vanco) for S. O I I Y C I I > ,  or ceftriaxone 
for streptococci. The risk of resistance selection was exmiiried. 
Against Cipro-susceptible S. atireus, all three new quinolones wzrc 
equivalent or  more active than Cipro and Vanco in vitro ~ n d  in VIVO, 
and were markedly less prone than Cipro to select for quinolone 
resistance. However, they were ineffective against S .  m r w s  alreddy 
resistant to Cipro. Two experimental quinolones (Y-688 . Ind S- 
34109) with high in vitro activity against Cipro-resistant S. airreics also 
failed in rats, arid selected for mutants with increased MICc. Thu\, 
once resistant to Cipro, S. aweus may eady  acquire addltioii3~ iiiutzl- 
tions, making it resistant to the most powerful quinolones. Against 
streptococci, levofloxacin was etfective against EE due to penicillin- 
susceptible and -resistant isolates. [n contrast, trovafloxacin failed in 
similar experiments. Time-kill experiments indicated that very low 
concentrations (X2 and X4 MIC) oflevofloxacin were more bacteri- 
cidal than trovafloxacin against streptococci, suggestmg that higher 
doses of this drug should be used in thir situation. This was not 
observed for S. aureus. We conclude that newer quinolones might be 
convenient and effective against Cipro-susceptible (but not -resictant) 
S. anreus and streptococcal infections. Moreover, they are lesc prone 
than older quinolones to select for resistance. 
[s1651 Anti-infective impregnation of vascular 
prostheses and cardiac prosthetic valves: 
rationale and experimental evidence 
J. Steckelberg, Mayo Clirric, I r $ ~ t i i ~ u ~  Disrascs arid Iritcrrral Afedicirw. 
Roriiestev, Mh: USA 
Anti-infective agents have been bound to a v3riety of iiiiplantable or  
indwelling medical devices in an attempt to increasc local concc~i- 
trations of antiiiiicrobial or antiseptic agent\ and to reduce the I-nk o f  
foreign body infections. This approach has been shown to be success- 
ful in some clinical settings (such a\ silver-coatzd intrava\cular 
catheters) but unsuccessful in others. For the prevention or trcatiiiciit 
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of vascular graft infections, a variety of anti-infectives bound to graft 
materials have been studied in vitro and under experimental in vivo 
conditions. Of these, gelatin-sealed Dacron grafts containing bound 
rifampin appear to have the most favorable pharmacokinetics in vitro. 
Experimental models demonstrate efficacy for the prevention of 
infection following contamination of the graft either directly or 
hematogenously, as well as efilcacy for the treatment of established 
infection when rifanipin-containing grafts are used as part of surgical 
therapy. To date, however, results reported from two randomized 
clinical trials involving over 3100 patients have not shown a statistic- 
ally significant reduction in graft infections. 
Both the incidence of endocarditis and the mortality among 
patients with endocarditis are higher among patients with cardiac 
prosthetic valves than among patients with native cardiac valves. 
Endocarditis affecting prosthetic cardiac valves typically originates in 
the sewing ring. Recently, St Jude prosthetic cardiac valves using 
Dacron sewing rings impregnated with silver (Silzone) have been 
introduced into clinical practice. In vitro, Silzone inhibits attachment 
and growth of microorganisms. A large, international randomized 
clinical trial designed to determine whether Silzone is effective in 
reducing the incidence of prosthetic valve endocarditis is in progress. 
Medical versus surgical therapy in native and 
prosthetic valve endocarditis 
C. Piper, R. Korfer, R. Hetzer, H.D. Schulte, D. Horstkotte. Heart 
Center Norrhrhine- Westfalia, University Hospital, Bad Oeynliausen; 
German Heart Center, Berlin; Heinrich-Hcine- University, Dusseldotj 
Germany 
Infective endocarditis (IE) of native and prosthethic heart valves is still 
burdened by a high mortality. While cumulative survival in uncom- 
plicated IE is 0.93+0.05, manifestation of any of the typical com- 
plications (e.g. congestive heart failure, thromboembolisin. persistent 
sepsis, acute renal failure), vegetation size 10 mni, culture-negative 
endocarditis and a delay in diagnostic decision-making has a signi- 
ficant negative prognostic influence. Early surgical intervention has 
significantly contributed to the overall prognostic improvement 
during the last two decades. Evidence-based experience with more 
than 600 consecutive patients with acute IE has been used to establish 
criteria to determine which patients may benefit from urgent surgical 
intervention: acute aortic regurgitation with lung edema not 
compensated medically within 24 h; acute mitral regurgitation with 
lung edema not compensated by PEEP; ventilation and modulation 
of the left ventricular impedance by sufficient afterload reduction; 
throniboembolic complications (TE) within 30 days after manifest- 
ation of IE, if residual vegetations are demonstrated post-TE; 
recurrent thromboembolic episodes; vegetations larger than 10 mm 
in mitral IE; demonstration of secondary mitral valve involvement in 
aortic IE; sepsis persisting for more than 48 h despite antimicrobial 
therapy; acute renal failure of any etiology; large vegetation size (VS) 
and a high minimal bactericidal concentration (MBC). Medical cure 
rates are low and the risk of complications is high if VS is 10 mm 
and MBC is 1 mg/L. 
Current aspects in anaerobic infections 
Js1681 Antimicrobial resistance in anaerobic bacteria 
E. Nagy. Department cf Clinical Mirrobioloxy, Albert Szent-Gydrgyi 
Medical University, Szeged, Hunpry 
Human pathogenic anaerobic bacteria were susceptible until a few 
years ago to antimicrobial agents used in prophylaxis and treatment 
of anaerobic infections. However, during recent years resistance to 
certain anti-anaerobic drugs has been reported more frequently from 
different parts of the world. The Etest method (more reliable than 
the disk diffusion method) has become available for routine labora- 
tories to evaluate the resistance of clinical isolates to most widely used 
antibiotics. Antibiotic resistance due to beta-lactamase activity is 
observed most frequently among Barfemides jagi l is  group strains; 
however, more and more Prerwtella, Porphyromonas and Fusobactrrium 
strains have been reported to be resistant to different antimicrobial 
agents. The nietallo-beta-lactamase production of B. fragilis is res- 
ponsible for the resistance to carbapenems. The presence of the Cf iA  
gene, coding for this enzyme, has been detected by PCR among 
carbapenem-susceptible strains in different parts of Europe. 
Decreased permeability and modification of the PBPs has also been 
reported as the cause of resistance to cefoxitin, ureidopenicillins and 
inhibitor combinations. Clindainycin resistance among clinically 
important anaerobes varies in different parts of the world. Among 
Gram-negative anaerobes, a low number of strains resistant to 
metronidazole have also been detected in different countries. 
According to the in vitro data, the newest fluoroquinolones, such as 
trovafloxacin, clinafloxacin and grepafloxacin, have considerable anti- 
anaerobic activity, 
Is169] Current aspects of anaerobic infections 
C.E. Nord. University Hospita/, Dept. <flmmuno/ofy, Huddingr, 
Sweden 
The normal human microflora contains both aerobic and anaerobic 
bacteria. The human gastric niucosa is colonized by the inhgenous 
bacteria in low numbers in healthy persons due to the low pH of the 
stomach. The bacteria are also protected from the gastric acid by the 
mucosal layer in the stomach. Impaired gastric secretion causes 
proliferation of acid-tolerant streptococci and lactobacilli. When the 
pH is constantly over 4, proliferation of other anaerobic bacteria such 
as bacteroides and fusobacteria can occur. These bacteria colonize the 
inucosa without any signs of mucosal inflammation, in contrast to 
Helitobacter pylori. It is now accepted that the finding of Heliiobarter 
pylori is associated with gastritis and peptic ulcer disease. Treatments 
for Helicobacter pylori infections include proton pump inhibitors in 
combination with antimicrobial agents with different clinical res- 
ponses. Probiotics containing anaerobic bacteria have also been 
reported to be successful in the treatment of these infections. In 
patients treated with a proton pump inhibitor, anaerobic bacteria 
such as veillonellae, bacteroides and fusobacteria are increased when 
HeliroBacterpylori is significantly decreased. Patients receiving a proton 
pump inhibitor together with antimicrobial agenh have also increased 
numbers of anaerobic bacteria when Helitobacter pylori is eradicated 
from the gastric microflora. Thus, there IS an inverse relationship 
between the anaerobic microflora and Heliiobacter pylori during 
proton pump inhibitor/antimicrobial treatment. 
